PDE5 inhibitor

Phase 3Small molecule

SSaint Petersburg State University, Russia

PDE5 inhibitor is one of 87 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

Prostate CarcinomaRecruiting

Erectile DysfunctionPreclinical

Active, not recruiting

Prostate CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

53 competitors in Erectile Dysfunction

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Approved

36 2

Levitra

Bayer

Approved

10 3

Viagra

VViatris Specialty LLC

Approved

13 4

Rifadin

Sanofi

Approved

1 5

Flomax

Cipro

Avandia

Norvir

Avelox

Caverject

VViatris Specialty LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Prostate Carcinoma

NCT06717711

Clinical

Trials by Indication[1]

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

Completed·—··NCT05039086·13,021 enrolled

Erectile Dysfunction1 trial

Efficacy and Safety of Focused Shockwave Therapy Plus Tadalafil vs Tadalafil Alone in Patient With Erectile Dysfunction

Unknown status·SSaint Petersburg State University, Russia·N/A·NCT05823506·36 enrolled

Prostate Carcinoma1 trial

Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers

Recruiting·RRegina Elena Cancer Institute·Phase 3·NCT06717711·158 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PDE5 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PDE5 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PDE5 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Saint Petersburg State University, Russia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSaint Petersburg State University, Russia

PDE5 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Drug Repurposing1 trial

Erectile Dysfunction1 trial

Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News